Medicines labeled for the same conditions
Alternatives to doravirine
42 other medicines are given the same way (oral) and in the same FDA class as doravirine or labeled mainly for the same use (HIV); 9 are in its class, human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitors: etravirine, nevirapine, efavirenz, efavirenz and emtricitabine and tenofovir disoproxil and 5 more; the others include 9 hepatitis b virus nucleoside analog reverse transcriptase inhibitors, 8 cytochrome p450 3a inhibitors and 5 human immunodeficiency virus integrase strand transfer inhibitors (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.147 per nevirapine 200 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as doravirine?
The first 24 of the 42, the same class first. HIV lists all 47 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Doravirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor | this medicine | none listed | $60.79 per tablet 100 mg tablet | No | No current entry |
| Etravirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 5 labelers | $9.94 per tablet 200 mg tablet | No | A presentation being discontinued |
| Nevirapinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 6 labelers | $0.147 per tablet 200 mg tablet | Yes | No current entry |
| Efavirenzhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 5 labelers | $1.28 per tablet 600 mg tablet | No | No current entry |
| Efavirenz and emtricitabine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 7 labelers | $1.12 per tablet 600-200-300 mg tablet | Yes | No current entry |
| Rilpivirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 2 labelers | $48.04 per tablet 25 mg tablet | No | No current entry |
| Efavirenz and lamivudine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 1 labeler | n/a | Yes | No current entry |
| Emtricitabine and rilpivirine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 2 labelers | $114.50 per tablet 200-25-300 mg tablet | Yes | No current entry |
| Dolutegravir and rilpivirinehuman immunodeficiency virus integrase strand transfer inhibitor · same class | HIV | none listed | $121.87 per tablet 50-25 mg tablet | No | No current entry |
| Emtricitabine and rilpivirine and tenofovir alafenamidehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $130.49 per tablet Odefsey tablet | Yes | No current entry |
| Emtricitabine and tenofovir disoproxilhepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 25 labelers | $0.529 per tablet 200-300 mg tablet | Yes | No current entry |
| Darunavirprotease inhibitor | HIV | 13 labelers | $1.16 per tablet 600 mg tablet | No | No current entry |
| Lamivudinehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 14 labelers | $0.489 per tablet 150 mg tablet | Yes | No current entry |
| Tenofovir disoproxilhepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 15 labelers | $0.294 per tablet 300 mg tablet | Yes | No current entry |
| Maravirocccr5 co-receptor antagonist | HIV | 8 labelers | $9.15 per tablet 150 mg tablet | Yes | A presentation being discontinued |
| Atazanavirprotease inhibitor | HIV | 4 labelers | $2.23 per capsule 300 mg capsule | No | No current entry |
| Abacavirhuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor | HIV | 12 labelers | $0.546 per tablet 300 mg tablet | Yes | No current entry |
| Lamivudine and zidovudinehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | Yes | No current entry |
| Ritonavircytochrome p450 3a inhibitor | HIV | 7 labelers | $0.607 per tablet 100 mg tablet | Yes | A presentation being discontinued |
| Lopinavir and ritonavircytochrome p450 3a inhibitor | HIV | 3 labelers | $4.46 per tablet 200-50 mg tablet | No | A presentation being discontinued |
| Raltegravirhuman immunodeficiency virus integrase strand transfer inhibitor | HIV | 1 labeler | $34.54 per tablet 400 mg tablet | No | No current entry |
| Zidovudinehuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor | HIV | 3 labelers | $0.464 per tablet 300 mg tablet | Yes | No current entry |
| Abacavir and lamivudinehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 6 labelers | $1.48 per unit 600-300 mg | Yes | No current entry |
| Dolutegravirhuman immunodeficiency virus integrase strand transfer inhibitor | HIV | none listed | $77.64 per tablet 50 mg tablet | No | No current entry |
| Bictegravir and emtricitabine and tenofovir alafenamidehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | none listed | $136.73 per tablet 50-200-25 mg tablet | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Doravirine: the full record
- label, generics, price, shortages, recalls